Figure 4 | Cell Death & Disease

Figure 4

From: MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies

Figure 4

ABT-199 in combination with NVP-BEZ235 sensitizes ABT199-R cells. Parental and resistant derivative DLBCL cell lines (a) SU-DHL-6 (b) SU-DHL-6 ABT199-R (c) OCl-Ly-19 ABT-199R (e) SU-DHL-16, and (d) FL cell line DOHH2 were treated with the indicated concentration of ABT-199 and NVP-BEZ235, alone and in combination for 24 h. Cell viability was determined by Annexin V-PI staining represented as percentage relative to control cells treated with dimethyl sulfoxide. Standard deviation (S.D.) is indicated by the error bars (N=3)

Back to article page